KRTX stock marks Karuna's USD 14 billion BMS deal

Published on 09/28/2026 at 20:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

KRTX stock marks Karuna Therapeutics' USD 14 billion Bristol Myers deal from 2024. The last quoted price was USD 329.83 on March 15, 2024.

KRTX, US5011311096, Illustration mit AI erstellt.

KRTX stock marks Karuna Therapeutics' USD 14 billion acquisition by Bristol Myers Squibb, a transaction that moved the biotech's lead schizophrenia program into a major pharmaceutical group. KRTX was last quoted at USD 329.83 on Nasdaq on March 15, 2024 at 4:00 p.m. ET, with a daily gain of 0.03 percent.

USD 14 billion deal defines Karuna

Investor's Business Daily reported on September 9, 2026, that Bristol Myers Squibb spent USD 14 billion in 2024 to acquire Karuna Therapeutics. The transaction centered on Karuna's drug that became Cobenfy, a schizophrenia treatment.

The acquisition changes how KRTX belongs in a stock analysis. Rather than serving as a standalone biotechnology listing, Karuna's central commercial asset is now part of Bristol Myers Squibb's neuroscience strategy, linking the former KRTX story to the larger drugmaker's pipeline and launch execution.

Historical quote near yearly high

The March 15, 2024 quote of USD 329.83 stood 0.05 percent below the 52-week high of USD 329.99 and above the 52-week low of USD 158.38. Trading volume was 1,283,005 shares on that session, while the market capitalization was USD 12.6 billion.

The pricing history shows why the transaction represented a decisive valuation event for Karuna shareholders: the last quoted price was more than double the low of the same 52-week period, while the stock remained close to its high. These figures are historical market context rather than a new trading signal for September 28, 2026.

Cobenfy keeps the asset in view

Evaluate identifies the Bristol Myers Squibb acquisition of Karuna as a headline central nervous system transaction and links it to Cobenfy. The publication also describes the 2024 approval of Cobenfy as the first non-dopaminergic schizophrenia treatment in over 30 years.

For investors researching KRTX, the key conclusion is structural: the former ticker is best understood through the USD 14 billion deal, the Cobenfy asset and Bristol Myers Squibb's subsequent neuroscience priorities. Karuna Therapeutics remains a relevant name in transaction history, even as the investment narrative is now attached to its acquirer.

KRTX quote remains historical

KRTX was last at USD 329.83 on Nasdaq on March 15, 2024 at 4:00 p.m. ET, with a market capitalization of USD 12.6 billion. Karuna Therapeutics, Inc. operated in the Healthcare sector and Biotechnology industry.